A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
CONCLUSION: This S-1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.
PMID: 30578309 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Yoshimura A, Chihara Y, Date K, Tamiya N, Takemura Y, Imabayashi T, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K Tags: Oncologist Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Docetaxel | Hematology | Interstitial Lung Disease | Lessons | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Study | Taxotere | Toxicology